ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report - Quiz - MDSpire

ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report

  • By

  • Danyang Zhou

  • Ying Wu

  • Siyu Guo

  • Ping Li

  • Guangxin Li

  • Mengqi Yang

  • Shubin Wang

  • Fang Yang

  • June 2, 2026

  • 0 min

Share

Original Source(s)

ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report

  • by Danyang Zhou, Ying Wu, Siyu Guo, Ping Li, Guangxin Li, Mengqi Yang, Shubin Wang, Fang Yang

  • June 2, 2026

Related Content

Case Report: Cytokeratin-positive interstitial reticulum cell tumor with HLA loss of heterozygosity

Multimodal feature fusion model for breast mass malignant risk stratification

ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma